3825 related articles for article (PubMed ID: 16705046)
1. Predictors of response to anti-TNF-alpha therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register.
Hyrich KL; Watson KD; Silman AJ; Symmons DP;
Rheumatology (Oxford); 2006 Dec; 45(12):1558-65. PubMed ID: 16705046
[TBL] [Abstract][Full Text] [Related]
2. Comparison of the response to infliximab or etanercept monotherapy with the response to cotherapy with methotrexate or another disease-modifying antirheumatic drug in patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register.
Hyrich KL; Symmons DP; Watson KD; Silman AJ;
Arthritis Rheum; 2006 Jun; 54(6):1786-94. PubMed ID: 16736520
[TBL] [Abstract][Full Text] [Related]
3. Rituximab therapy in patients with rheumatoid arthritis refractory or with contraindication to anti-tumour necrosis factor drugs: real-life experience in Finnish patients.
Valleala H; Korpela M; Möttönen T; Hienonen-Kempas T; Kauppi M; Hannonen P; Leirisalo-Repo M
Scand J Rheumatol; 2009; 38(5):323-7. PubMed ID: 19585384
[TBL] [Abstract][Full Text] [Related]
4. Real-world effectiveness of select biologic and DMARD monotherapy and combination therapy in the treatment of rheumatoid arthritis: results from the RADIUS observational registry.
Weaver AL; Lautzenheiser RL; Schiff MH; Gibofsky A; Perruquet JL; Luetkemeyer J; Paulus HE; Xia HA; Leff JA;
Curr Med Res Opin; 2006 Jan; 22(1):185-98. PubMed ID: 16393444
[TBL] [Abstract][Full Text] [Related]
5. Very early treatment with infliximab in addition to methotrexate in early, poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal: results from a twelve-month randomized, double-blind, placebo-controlled trial.
Quinn MA; Conaghan PG; O'Connor PJ; Karim Z; Greenstein A; Brown A; Brown C; Fraser A; Jarret S; Emery P
Arthritis Rheum; 2005 Jan; 52(1):27-35. PubMed ID: 15641102
[TBL] [Abstract][Full Text] [Related]
6. Effectiveness of rituximab in patients with rheumatoid arthritis: observational study from the British Society for Rheumatology Biologics Register.
Soliman MM; Hyrich KL; Lunt M; Watson KD; Symmons DP; Ashcroft DM;
J Rheumatol; 2012 Feb; 39(2):240-6. PubMed ID: 22174201
[TBL] [Abstract][Full Text] [Related]
7. Predictors of response to anti-TNF therapy according to ACR and EULAR criteria in patients with established RA: results from the South Swedish Arthritis Treatment Group Register.
Kristensen LE; Kapetanovic MC; Gülfe A; Söderlin M; Saxne T; Geborek P
Rheumatology (Oxford); 2008 Apr; 47(4):495-9. PubMed ID: 18316338
[TBL] [Abstract][Full Text] [Related]
8. Influence of variants of Fc gamma receptors IIA and IIIA on the American College of Rheumatology and European League Against Rheumatism responses to anti-tumour necrosis factor alpha therapy in rheumatoid arthritis.
Cañete JD; Suárez B; Hernández MV; Sanmartí R; Rego I; Celis R; Moll C; Pinto JA; Blanco FJ; Lozano F
Ann Rheum Dis; 2009 Oct; 68(10):1547-52. PubMed ID: 18930989
[TBL] [Abstract][Full Text] [Related]
9. Anti-TNF-alpha agents are less effective for the treatment of rheumatoid arthritis in current smokers.
Abhishek A; Butt S; Gadsby K; Zhang W; Deighton CM
J Clin Rheumatol; 2010 Jan; 16(1):15-8. PubMed ID: 20051749
[TBL] [Abstract][Full Text] [Related]
10. Lymphoma in rheumatoid arthritis: the effect of methotrexate and anti-tumor necrosis factor therapy in 18,572 patients.
Wolfe F; Michaud K
Arthritis Rheum; 2004 Jun; 50(6):1740-51. PubMed ID: 15188349
[TBL] [Abstract][Full Text] [Related]
11. Assessment of anti-TNF-alpha efficacy in rheumatoid arthritis: is 3 months sufficient?
Pocock JM; Vasconcelos JC; Ostör AJ
Rheumatology (Oxford); 2008 Jul; 47(7):1073-6. PubMed ID: 18503089
[TBL] [Abstract][Full Text] [Related]
12. Comparison of anti-TNF treatment initiation in rheumatoid arthritis databases demonstrates wide country variability in patient parameters at initiation of anti-TNF therapy.
Pease C; Pope JE; Truong D; Bombardier C; Widdifield J; Thorne JC; Paul Haraoui B; Psaradellis E; Sampalis J; Bonner A
Semin Arthritis Rheum; 2011 Aug; 41(1):81-9. PubMed ID: 21168187
[TBL] [Abstract][Full Text] [Related]
13. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks.
Cohen SB; Emery P; Greenwald MW; Dougados M; Furie RA; Genovese MC; Keystone EC; Loveless JE; Burmester GR; Cravets MW; Hessey EW; Shaw T; Totoritis MC;
Arthritis Rheum; 2006 Sep; 54(9):2793-806. PubMed ID: 16947627
[TBL] [Abstract][Full Text] [Related]
14. Highest clinical effectiveness of rituximab in autoantibody-positive patients with rheumatoid arthritis and in those for whom no more than one previous TNF antagonist has failed: pooled data from 10 European registries.
Chatzidionysiou K; Lie E; Nasonov E; Lukina G; Hetland ML; Tarp U; Gabay C; van Riel PL; Nordström DC; Gomez-Reino J; Pavelka K; Tomsic M; Kvien TK; van Vollenhoven RF
Ann Rheum Dis; 2011 Sep; 70(9):1575-80. PubMed ID: 21571731
[TBL] [Abstract][Full Text] [Related]
15. Rheumatoid factor positivity rather than anti-CCP positivity, a lower disability and a lower number of anti-TNF agents failed are associated with response to rituximab in rheumatoid arthritis.
Quartuccio L; Fabris M; Salvin S; Atzeni F; Saracco M; Benucci M; Cimmino M; Morassi P; Masolini P; Pellerito R; Cutolo M; Puttini PS; De Vita S
Rheumatology (Oxford); 2009 Dec; 48(12):1557-9. PubMed ID: 19789202
[TBL] [Abstract][Full Text] [Related]
16. The prevalence of patients with rheumatoid arthritis in the West Midlands fulfilling the BSR criteria for anti-tumour necrosis factor therapy: an out-patient study.
Yee CS; Filer A; Pace A; Douglas K; Situnayake D; Rowe IF;
Rheumatology (Oxford); 2003 Jul; 42(7):856-9. PubMed ID: 12730544
[TBL] [Abstract][Full Text] [Related]
17. Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: results from eight years of surveillance of clinical practice in the nationwide Danish DANBIO registry.
Hetland ML; Christensen IJ; Tarp U; Dreyer L; Hansen A; Hansen IT; Kollerup G; Linde L; Lindegaard HM; Poulsen UE; Schlemmer A; Jensen DV; Jensen S; Hostenkamp G; Østergaard M;
Arthritis Rheum; 2010 Jan; 62(1):22-32. PubMed ID: 20039405
[TBL] [Abstract][Full Text] [Related]
18. Rituximab therapy in patients with resistant rheumatoid arthritis: real-life experience.
Jois RN; Masding A; Somerville M; Gaffney K; Scott DG
Rheumatology (Oxford); 2007 Jun; 46(6):980-2. PubMed ID: 17384180
[TBL] [Abstract][Full Text] [Related]
19. Relationship between pack-year history of smoking and response to tumor necrosis factor antagonists in patients with rheumatoid arthritis.
Mattey DL; Brownfield A; Dawes PT
J Rheumatol; 2009 Jun; 36(6):1180-7. PubMed ID: 19447930
[TBL] [Abstract][Full Text] [Related]
20. Clinical significance of synovial lymphoid neogenesis and its reversal after anti-tumour necrosis factor alpha therapy in rheumatoid arthritis.
Cañete JD; Celis R; Moll C; Izquierdo E; Marsal S; Sanmartí R; Palacín A; Lora D; de la Cruz J; Pablos JL
Ann Rheum Dis; 2009 May; 68(5):751-6. PubMed ID: 18495732
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
